Роль и место мелатонина в патогенезе и лечении воспалительных заболеваний кишечника и рака толстой кишки
Диссертация
Известно, что апоптоз принимает участие не только в «программируемой» гибели клеток, но и в удалении некоторых клеток при пролиферации клеточной популяции, гибели отдельных клеток в опухолях, в основном при ее регрессии, но также и в активно растущей опухоли и др. Путем программированной клеточной гибели происходит удаление клеток, выживание которых нежелательно для организма, например мутантных… Читать ещё >
Список литературы
- Аббасова С.Г. и др. Система Fas-FasL в норме ишри патологии /Аббасова С.Г., Липкин В. М., Трапезников Н: Н., Кушлинский Н. Е. //Вопросы биол. мед. и фарм. химии. — 1999. № 3. — СЗ-16.
- Адлер Г. Болезнь Крона и язвенный колит. / Адлер Г. М. — ГЭОТАР— МЕД.-2001.
- Александров В.Б. Лапароскопические технологии в колоректальной хирургии. / Александров В. Б. М. — Медпрактика. — 2003.
- Александров В.Б. Рак прямой кишки. / Александров В.Б. М. Вузовская книга. — 2006.
- Анисимов В. Н Влияние мелатонина и эпиталамина на активность антиоксидантной системы у крыс. / Анисимов В. Н., Арутюнян A.B., Хавинсон В. Х. // Доклады РАН. 1997. — Т. 352. — С. 831−833.
- Анисимов В.Н. Мелатонин и эпиталамин угнетают процесс перекисного окисления липидов у крыс / Анисимов В. Н., Арутюнян A.B., Хавинсон В. Х. // Доклады РАН. 1996. — Т. 348. — С. 765−767.
- Анисимов В.Н. Мелатонин и эпиталамин угнетают процесс свободно-радикального окисления у крыс / Анисимов В. Н., Прокопенко В. М., Хавинсон В. Х. / / Доклады РАН. 1995. — Т.343. — С. 557−559.
- Анисимов C.B. Изучение влияния мелатонина на экспрессию генов в сердце мышей с помощью микрочиповой технологии / Анисимов C.B., Богилер K.P., Анисимов В. Н. // Докл.РАН. 2002. — Т.383. — С.276−281.
- Аруин Л. О. Морфологическая диагностика болезней желудка и кишечника. Аруин Л. О., Капуллер Л. Л., Исаков В. И. М.: Триада-Х -1998.-С.496.
- Белоусова Е.А. Иммунные механизмы при воспалительных заболеваниях кишечника и методы селективной иммунокоррекции. Российский журналгастроэнтерологии, гепатологии, колопроктологии. / Белоусова Е. А // -1999-Т. IX. № 4. — Прилож. 7. — С. 48−57.1. N 1 «*
- Белоусова Е.А. Терапия воспалительных заболеваний кишечника: настоящее и будущее / Белоусова Е. А. // Врач 2002. — № 2. — С. 36−39.
- Белоусова Е.А. Медиаторы воспаления при язвенном колите и болезни Крона / Белоусова Е. А., Златкина А. Р. // Международные медицинские обзоры. 1993. -№ 5. — С. 378−386.
- Белоусова Е.А. Пролиферативная активность толстокишечного эпителия при язвенном колите / Белоусова Е. А., Златкина А. Р., Казанцева И./Г., Исаков В. А. //Материалы научной сессии ЦНИИГ. -М., 1998'.
- Белоусова Е.А. Опыт применения сандостатина при язвенном колите и болезни Крона / Белоусова Е. А., Златкина А. Р., Никулина И. В. // Российский журнал гастроэнтерологии и гепатологии. 1994. № 3. — С. 8891.
- Белоусова Е.А. Генетические аспекты гормонорезистентности при ВЗК / Белоусова Е. А., Морозова H.A. // Российский журнал гастроэнтерологии, г гепатологии, колопроктологии. 1999. — № 5. — Прилож. 8. — № 213.
- Белушкина H.H. Молекулярные основы патологии апоптоза / Белушкина H.H., Северин С.Е.// Архив патол. 2001. — № 1. — С.51−60.
- Бондаренко JI.A. Современные представления о физиологии эпифиза / Бондаренко JI.A. // Нейрофизиология. 1997. — Т.29. — С. 121−237.
- Бреус Т.К. Магнитные бури медико-биологические и геофизические аспекты / Бреус Т. К., Рапопорт СМ.// - М. „Советский спорт“. — 2003. ч*
- Гарин A.M. Рак толстой кишки. Современное состояние проблемы. / Гарин A.M. // -М. ИЧП Фирма „Рича“. 1998.
- Златкина А.Р. Фармакотерапия хронических болезней органов пищеварения / Златкина А. Р. //- М.: Медицина. 1998. — С.288.
- Ивашкин В. Т. Выбор лекарственной терапии воспалительных заболеваний кишечника / Ивашкин В. Т. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 1997. — Т. 8. — № 6. — С. 41−47.
- Кветной И.М. APUD-система (структурно-функциональная организация, биологическое значение в норме и патологии) / Кветной И. М. // Усп.физиол.наук. 1987. — № 18. — С.84−102.
- Кветной И.М. APUD-система и функция желудочно-кишечного тракта: экспериментальное исследование / Кветной И. М., Райхлин Н. Т., Соломатина Т. М. // Сов. Мед. — 1983. — № 6. — С.53−59.
- Киркин Б.В. Рак толстой кишки у больных неспецифическим язвенным колитом / Киркин Б. В., Капуллер JI. JL, Маят К. Е. и др. // Клиническая-медицина. 1988. — № 9. -С. 108−113.
- Коваленко Р.И. Нейроэндокринные „органы“ головного мозга позвоночных. „Нейроэндокринология“ / Коваленко Р. И. // 1. Эпифиз В кн.: Под редакцией A.JI. Поленова. (Основы современной физиологии). Часть 1. Книга вторая. РАН СПб.- 1993. — С. 300−324.
- Козлова И.В. Мелатонин и серотонин при воспалительных заболеваниях толстой кишки и колоректальном раке / Козлова И. В., Осадчук M. A, Кветной И. М., Кветная Т. В. и др. // Клин. мед. 2000. — № 6. — С.32−36.
- Комаров Ф.И. Мелатонин в норме и патологии / Комаров Ф. И., Рапопорт С. И., Малиновская Н. К., Анисимов В. Н. // ИД МЕДПРАКТИКА-М. 2003.
- Левитан М.Х. Неспецифические колиты / Левитан М. Х., Федоров В. Д., Капуллер Л. Л // -М.: Медицина.- 1980. С. 280.
- Лушников Е.В. Апоптоз клеток: морфология, биологическая роль, механизмы развития / Лушников Е. В. Загребин В.М. //Архив патол. 198v7. -Т.49. — С.84−89.
- Насонов E.JI. Нарушения иммунитета при- аутоиммунных заболеваниях / Насонов Е. Л. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 1999. T. IX. — № 4. — Прилож. 7. — С. 43−48.
- Никитина Н. В. Диагностическое и прогностическое значение тканевых эмбриональных антигенов при язвенном колите: Автореф. дисс. канд. мед. наук. / Никитина Н. В. // М.- 1999. — С.24.
- Осадчук М.А. Диффузная нейроэндокринная система: общепатологическйе и гастроэнтерологические аспекты / Осадчук М. А., Киричук В. Ф., Кветной И. М. // Саратов. Изд-во Саратовского университета. — 1996. — Р.128.
- Парфенов А.И. Энтерология. / Парфенов А. И. // Триада. М. 2002.
- Райхлин Н.Т. APUD-система (общепатологические и онкологические аспекты) / Райхлин Н. Т., Квитной И. М., Осадчук М. А. // Обнинск. 1993. -С.225.
- Румянцев В.Г. Фальк симпозиум в Москве. / Румянцев В. Г. // Тер. АрхивГ— 2007.-том 2. С. 91−93.
- Уманский С.Р. Апоптоз: молекулярные и клеточные механизмы / Уманский С. Р. // Молекулярная биология. -1996. Т. 30, № 3. — С.487−502.
- Хавинсон В.Х. Пептидные биорегуляторы ингибируют апоптоз / Хавинсон
- B.Х., Кветной И. М. // Бюлл. экспер. биол. и мед. 2000. — № 12. — С. 657 659.
- Хомерики С.Г. Процессы регенерации в слизистой оболочке желудка и канцерогенез / Хомерики С. Г. // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2001. — № 2. — С. 17−21.
- Ярилин A.A. Апоптоз. Природа феномена и его роль в целостном организме / Ярилин A.A. // Патол. физиол. эксп. терап. 1998. — № 2.1. C.38−48.
- Ahnen D.J. Search of a specific marker of mucosal dysplasia in chronic ulcerative colitis /Ahnen D.J., Warren G.H., Greene L.J. et al. // Gastroenterology. 1987. -V. 93.-P. 1346−1355.
- Allan R.N. Cancer risk in ulcerative colitis and Crohn’s disease / Allan R.N. // Inflammatory bowel disease / Edit. By G. Jarnerot.- 1992. P. 551−568.
- Allan R.N. The APUD concept: where has it led us? / Allan R.N. // Brit. Med. Bull. 1982. — V.38. — P.221−225.
- Ang Y.S. Randomised comparision of unfractionated heparin with---corticosteroids in severe active inflammatory bowel disease / Ang Y.S., Mahmud N., White B., Byrne M. et al. // Aliment. Pharmacol. Ther. 2000. — V. 14.-P. 1015−1022.
- Anisimov V.N. Caricinogenesis and aging. / Anisimov V.N. // V. 2. Boca Raton, Florida: CRC Press. ~ 1987. P. 148.
- Anisimov V.N. Life span extension and cancer risk: myths and reality / Anisimov V.N. // Exp Geront. 2001. — V.36. — P. 1101−1136.
- Anisimov V.N. Melatonin and colon carcinogenesis / Anisimov V.N. // In: C. Bartsch H., Bartsch, D.E.Blask et al.(eds.). The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer. 2001. -P. 240−258.
- Anisimov V.N. Dose-dependent effect of melatonin on life span and speontaneous tumor incidence in female SHR mice / Anisimov V.N., Alimova I.N., Baturin D.A. et al. // Exp. Gerontol. -2003.-V.38. P. 449−461.
- Anisimov V.N. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice / Anisimov V.N., Alimova I.N., Baturin D.A. et al. // Int. J. Cancer. 2003a. — V.103. — P.300−305.
- Anisimov V.N. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal, tumours induced by 1,2-dimethylhydrazine in rats / Anisimov V.N., Popovich I.G., et al. // Carcinogenesis. 1997. — V.18. — P. 1549−1553.
- Arendt J. Human responses to light and melatonin. / Arendt J. // In: Advances in Pineal Research. London — 1994. — V.8. — P.439−441.
- Arendt J. Melatonin and- mammalian pineal1 gland. / Arendt» J. // London. -Chapman & Hall. — 1995. -P.331.
- Arendt J. Melatonin and the mammalian pineal gland. / Arendt J. // Chapman & Hall.- London. — 1995.-P. 331.
- Armstrong S.M. Melatonin: a chronobiotic with anti-aging properties? / Armstrong S.M., Redman J.R. // Med Hypotheses. 1991. — V.34. — P.300−309.
- ASCRS Dis. C&R. 2004. — V.47. — P.807−15.
- Banerjee S. Mitotic arrest by melatonin. / Banerjee S., Margulis L. // Exp. Cell Res. 1973. — V.78. -P.314−318.
- Barni S. A study of the pineal hormone melatonin as a second-line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. / Barni S., Lissoni P., Paolorossi F. et al. // Tumor. 1990. — V.76. — P.58−60.
- Barter R. Mammalian enterochromoffine cell as the source of serotonin (5— hydroxytryptamine). / Barter R., Pearse A.G.E. // J. Pathol. Bacteriol. 1955. -V.69. — P.25−31.
- Bartsch C. The pineal gland and cancer. / Bartsch C., Bartsch H., Blask D.E. et al. (eds). // Neuroimmu-noendocrine mechanisms in malignancy. Berlin: Springer. 2001. — 578 p.
- Bartsch H., Bartsch C., et al. The relationship between the pineal gland and cancer- seasonal aspects. / Bartsch H., Bartsch C., et al. // In: L. Wetterberg (eds). Light and biological rhythms in man. Pergamon Press. 1993. — P.337−350.
- Bartusel T. Regulation of the cyclin D1 and cyclin Al promoters by B-Myb is mediated by Spl binding sites. / Bartusel T., Schubert S., Klempnauer K.N. // Gene. 2005 May 23:351:171−80.
- Bates S.E. Use of serum tumor markers in cancer diagnosis and management. / Bates S.E., Longo D.L. // Sem.Oncol. 1987. — V.14. — P. 102.
- Beck N.E. Frequency of germline hereditary non-polyposis colorectal cancer gene mutations in patients with multiple or early onset colorectal adenomas. / Beck N.E. Tomlinson J.P.M., Homfray T.F.R., et al. // Prog. In colorect.Canc. -1998.-V.2.-P.25.
- Befrits R. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. / Befrits R., Hammarberg C., Rubio C. et al. // Dis. Colon. Rectum. 1994. — V. 37. — P. 313−320.
- Belaiche J. Initial medical management of severe acute UC./ Belaiche J., Louis E. // Acta Gastro-Enterologica Belgica. — 2000. — V. 63. — Fasc. 3 — P. 275 278.
- Bell S.J. Anti-TNF-a antibody therapy treatment for Crohn’s disease. / BellS.J., Kamm M.A. // IBD, salicylates and other relevant therapies. Proceeding of the International IBD Symposium. — London, 1999. — P. 129−138.
- Belluzii A. Polyunsaturated fatty acids and inflammatory bowel disease. / Belluzii A., Boschi S., Brignola C., MunariniA. et al. // Am. J. Clin. Nutr. -2000. V. 71 (suppl. S). — 339S-342S.
- Bernstein C.N. Cancer risk in patients with inflammatory bowel disease. A population-based study. / Bernstein C.N., Blanchard J.F., Kliever- E., Wajda A. // Cancer 2001. -V. 91.-P. 854−862.
- Best W.R. Development of Crohn’s disease activity index. National Cooperative Crohn’s disease Study. / Best W.R., Becktel J.M., Singleton J. W. et al. // Gastroenterology. 1976. — V. 70. — P. 439−444.
- Binder V. Intestinal cancer risk in patients with inflammatory bowel disease. / Binder V., Langholz E., Munkholm P. // Malignancy and chronic inflammation in the gastrointestinal tract new concepts. Kluwer. Academic Publishers. -1995.-P. 101−104.
- Blask D.E. Melatonin in oncology. In: «Melatonin. Biosynthesis, physiological effects, and, clinical applications». / Blask D.E. // H.-S.Yu, R.J.Reiter.(eds.). Boca Raton, FL: CRC Press. 1993. — Y. 14. — P. 447−475.
- Blask D.E. The pineal: an oncostatic gland. / Blask D.E. // In: R.J. Reiter (ed). The pineal gland. New York: Raven Press. 1984. — P.253−284.
- Blask D.E. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. / Blask D.E., Hill S.M. // J. Neural Transm. (Suppl). -1986.-V. 21.-P. 433−449.
- Blask D.E. Melatonin and cancer: basic and clinical aspects. / Blask D.E., Hill S.M. // In: Miles A., Philbrick D.R.S., Thompson C. (eds). Melatonin: clinical perspectives. New York: Oxford Univ. Press. 1988. — P. 128−173.
- Bleiberg H. Adjuvant therapy in high-risk colon cancer. / Bleiberg H. // Semin Oncol. 2000. — V.27. — P. 48−59.
- BrainardG.C. The relationship between-electromagnetic field and light exposure to melatonin and’breast cancer risk: a review of the relevant literature. / Brainard G.C., Kaver R., Kheifets L.I. // J. Pineal’Res. 1999. — V.26. — P. 65−100.
- Brentnall T.A. Risk factors for development of cancer in IBD. / Brentnall T.A. // Int. Symposium of IBD «Advances in inflammatory bowel diseases». 1998. — № 106.-P. 33.
- Brentnall T.A. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. / Brentnall T.A., Crispin D.A., Rabinovitch PS. et al. // Gastroenterology. 1994. — V. 107. — P. 369−378.
- Breuer-Katschinsky B. Long-term use of nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. / Breuer-Katschinsky B., Nemes K., Rump B., Leiendecker B. et al. // Digestion. 2000. — V. 61. — P. 129−134.
- Broome U. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. / Broome U.3 Lofberg R. // Hepatology. 1995. -V 22−1404.
- Bubenik G.A. Diurnal variation and binding characteristics of melatonin in the mouse brain and gastrointestinal tissues. / Bubenik G.A. et al. // Comp. Biochem. Phisiol. C. 1993. — V. 104. -P.221−224.
- Bubenik G.A. Localization and physiological significance of gastrointestinal melatonin. / Bubenik G.A. // In: E. Watson (ed). Melatonin in health promotion. Boca Raton: CRC Books. 1999. — P. 21−39.
- Bubenik G.A. The effect of serotonin, N-acetylserotonin and melatonin on spontaneous contractions of isolated rat intestine. / Bubenik G.A. // J. Pineal Res. 1986. — V.3. — P.42−54.
- Bubenik G.A. Influence of serotonin and melatonin on some parameters of gastrointestinal activity. / Bubenik G.A., Dhanvantari S. // J. Pineal Res. 1989. — V.7. — P.333−344.
- Bubenik G.A. Melatonin concentration in serum and tissues of porcine gastrointestinal tract and their relationship to the intake and passage of food. / Bubenik G.A., Pang S.F., Hacker R.R., Smith P. S. // J. Pineal Res. 1996. -V.21.-P.251−256.9sr
- Burchill S.A. Mechanism of basic fibroblast growth factor-induced cell death / Burchill S.A., Westwood G. // Apoptosis. 2002. — № 1. — 5−12.
- Burkitt D. Effect of dietary fibre on stools and transit-times and its role in the causation of disease. / Burkitt D. // Lancet. 1978. — P.1278−1279.
- Burkitt D. Epidemiology of cancer of the colon and rectum. / Burkitt D. // Cane. -1971.-V.28.-P.3−13.
- Carbott D.E. Phosphoimositol 3 kinase inhibitor, LY294002 increases bcl-2 protein and inhibits okadaic acid-induced apoptosis in Bcl-2 expressing renal epithelial crlls. / Carbott D.E., Duan L., Davis M: A. // Apoptosis. 2002. — N. 1. — P. 69−76.
- Cohen M. Role of pineal gland in aetiology and treatment of breast cancer. / Cohen M., Lippman M., Chabner R. // Lancet. 1978. — V.2. — P.814−816.
- Cohen R.D. Intravenous cyclosporin in ulcerative colitis: a five-year experience. / Cohen R.D., Stein R., Hanauer S.B. //Am. J. Gastroenterol. 1999 -V 94 -P. 1587−1592.
- Cohen R.D. A meta-analysis and overview of the literature on treatment options for left-side ulcerative colitis and ulcerative proctitis. / Cohen R.D., Woseeh D.M., Thisted R.A., Hanauer S.B. // Am. J. Gastroenterol. 2000. — V. 95. — P. 1263−1276.
- Collins R.H. Colon cancer, dysplasia and surveillance in patients with ulcerative colitis. / Collins R.H., Feldman M., Fordtran J.S. //N.Eng.J.Med. 1987 -V.316 -P.1654.
- Colombel J.F. Etiology of Crohs disease: / Colombel J.F., Gower Rousseau C. I I Current data (editorial). Presse-Med. 1994. — V.26 (№ 23). — P: 558−560-
- Connel W.R. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. / Connel W.R., Lennard-Jones J.F., Williams C.B. et al. // Gas-troenterology. 1994. — V. 107. — P. 934−944.
- Conti A. Melatonin, rhythms in mice: role in autoimmune and lympho-proliferative diseases. / Conti A., Maestroni G.J. // Ann. N.Y. Acad. Sci. 1998. -V. 840.-P.395−410.
- Cos S. Effects of melatonin on the cell cycle kinetics- and «estrogen-rescue» of MCF-7 human breast cancer cells in culture. / Cos S., Blask D.E., Lemus-Wilson A., Hill A.B. // J. Pineal Res. 1991. — V.10. — P.36−42.
- Cos S. Melatonin and mammary pathological growth. / Cos S., Sanchez-Barcelo E.J. // Front. Neu-roendocrin. 2000. — V.17. — P. 133−170.
- Cos S. Effects of melatonin on the proliferation and differentiation of human neuroblastoma cells in culture. / Cos S., Verguda R., Ferenandez-Viadero C. et al.//Neurosci. Lett. 1996. — V.216. — P. 113−116.
- Costa R.S. Nitric oxide ingibits irreversibly P815 cell proliferation: involvement of potassium channels / Costa R.S., Assreuy J. //Cell Prolif. 2002 Dec- 35(6):321−32.
- Curran M.E. Genetic analisis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. / Curran M.E., Lau K.F., Натре J., Schrieber S. et al. // Gastroenterology. 1998. — V. 115. — № 5 -Г. 1066−1071.
- Dalton H.R. The immunology of inflammatory bowel disease. / Dalton H.R., Jewell D.P. // Inflammatory Bowel Disease / Ed. by G. Jarnerot. 1992. — P. 125−147.
- Daniel Otchy. Practice parameters for colon cancer. / Daniel Otchy, M.D., Neil H. Hyman, M.D., Clifford Simmang et al. // Dis Colon Rectum. 2004. — V.47. -P. 1269−1284.
- Davis S. Residental magnetic fields, light-at-night and nocturnal urinary 6-sulfatoxymelatonin concentration in women. / Davis S., Kaune W.T., et al. // Am. J. Epidemiol. -2001. V. 154. -P.591−600.
- Deerberg F. Effect of melatonin and physiological epiphysectomy on the developmet of spontaneous endometrial carcinoma in BDII/HAN rats II Cancer Biother. / Deerberg F., Bartsch C., Pohlmeyer G., Bartsch H. // Radiopharmacol. 1997.-V. 12.-P. 420.
- D’Haens G. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. / D’Haens G., Lemmens L, Geboes K., Vanderputte L. et al. // Gastroenterology. 2001.-V. 120. — P. 1323−1329.
- Diez M. Prognostic significance of pre-operative serum CA-19−9 assay in patients with colorectal cancinoma. / Diez M. Cerdan F.J., Pollan M., rt al. // Anticanc.Res. 1994. — Y.14. -P. 2819−2825.
- Eaden J. Colorectal cancer prevention in ulcerative colitis: a case-control-study. / Eaden J., Abrams K., Ekbom A., Jackson E. et al. // Aliment. Pharmacol. Ther. 2000 — V. 14.-P. 145−153.
- Eaden J. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. / Eaden J., Abrams K., Mayberry J.F. // Gut. 2001. — V. 48. — P. 526−535.
- Ehrenpreis E.D. Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. / Ehrenpreis E.D., Kane S. V., Cohen L.B., Hanauer S.B. //Gastroenterology. 1999-V. 117.-P. 1271−1277.
- Ekbom A. The IBD epidemiology. / Ekbom A. // A report from the 1-st International meeting on chronic Inflammatory Bowel Diseases. Madrid."-2000.-May 4−5.
- Ekbom A. Ulcerative colitis and colorectal cancer, a population-based study. / Ekbom A., Helmick C., ZackM., AdamiH.O. // N. Engl. J. Med. 1990. — V. 323.-P.1228−1233.
- Ekbom A. Sulphasalazine use as a preventive factor for colorectal cancer in ulcerative colitis patients a review (Clinical review). / Ekbom A., Kornfeld D. // IBD. — 1996. — V. 2. — № 4. — P. 276−278.
- Elson CO. The effects of immunosuppressive agents on cytokines. / Elson CO // Aliment. Pharmacol. Ther. 1996. -V. 10. — Suppl. 2. — P. 100−105.
- Emmrish J. Monoclonal antibodies and interleukins. / Emmrish J. // Innovative Concepts in Inflammatory Bowel Diseases. International Symposium on IBD. -1998.-P. 74.
- Erspamer V. Identification of enteramine, the specific hormone of the enterochromoffine cell system, as 5-hydroxytryptamine. / Erspamer V., Asefo B. //Nature. 1952. — V.169. — P.800−801.
- Farmer R. G. Cancer risk in ulcerative colitis. / Farmer R. G. // Scand. J. Gastroenterol. 1989. -V. 24.-P. 75−77.
- Feagan B. G. Infliximab in the treatment of Crohn’s disease. / Feagan B. G. // Scand. J. Gastroenterol. 2000. — V. 14. — Suppl. C. — 6B.
- Feagan B. G. A comparison of metho-trexate^with placebo for the maintenance of remission in Crohn’s disease. / Feagan B. G., Fedorak R.N., Irvine E.J., Wild G. et al. //N. Engl. J. Med. 2000. -V. 342. — P. 1627−1632.
- Fedorak R. N. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. / Fedorak R. N., Gangl A., Elson C. O., Rutgeerts P. et al. // Gastroenterology. 2000. — V. 119. — P. 1473−1482.
- Fellerman K. Steroid unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). / Fellerman K.5 Ludwig D., Stahl M., David-Walek T. el al. // Am. J. Gastroenterol. 1998. — V. 93. — № io -P. 1860−1866.
- Fellerman K. Mycophenolate-mofetil: lack of efficacy in chronic active inflammatory bowel disease. / Fellerman K., Steffen M., Stein J., Readier A. et al. // Aliment. Pharmacol. Ther. 2000.-V. 14.-P. 171−176.
- Fiocchi C. Pitfalls in cytokine analysis in inflammatory bowel disease. / Fiocchi C, Fukushima K., Strong S.A., Ina K. // Aliment. Pharmacol. Ther. 1996. — V. 10.-P. 63−71.
- Fiocchi C. High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives. / Fiochi C., Roshe J.K., Mishener W.M. // Ann. Intern. Med. 1989. — V. 110 (10). — P. 786−794.
- Fioretti M.C. Study on the type of antiserotoninergic antagonism exerted in vitro on rats stomach by pineal indole derivates. / Fioretti M.C., Menconi E., Riccardi C. //Farmacol. 1976. — V.29. -P.401−412.
- Fitzgerald T.J. Melatonin antagonizes colchicine-induced mitotic arrest. / Fitzgerald T.J., Veal A. // Experientia. 1976. — V.32. — P. 372−373.
- Fong Y. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer Ann Surg. / Fong Y. et al. // 1999. — V.230. — P. 309−21'.
- Fong W.E., Leung C.H., Lam W. et al. Epidermal growth factor induces Gadd45 (growth arrest and DNA damage inducible protein) expression in A431 cells //Biochi Biophys Acta. 2001. — 1517:250−256.
- Friedman S. Screening and surveillance colonoskopy in chronic Crohn’s disease. / Friedman S., Rubin P.H., Goldstein E., Harpaz N. et al. // Gastroenterology. -2001. -V.I 20.-P. 820−826.
- Frieri G. II Rectal and colonic mesalazine concentration in ulcerative colitis oral vs oral plus topical treatment. / Frieri G., Pimpo M.T., Palumbo G.C., Onori L. et al//Aliment. Pharmacol. Ther. 1999.-V. 13.-P. 1413−1417.
- FrieriG. Prevention of post-operative recurrence of Crohn’s disease requires adequate mucosal concentration of mesalazine. / FrieriG., PimpoM.T., AndreolliA., Armese V. et al. // Aliment. Pharmacol. Then, 1999. -V. 13.-P. 557−582.
- Fry D.E. Antibiotics in surgery. An overview. / Fry D.E. // Am J Surg. 1988. -V.155 -P.11−5.
- Fujino Y. Job stress and mental health among permanent night workers. / Fujino Y., Mizroue T., Izumi H., et al. // J. Occup. Health. 2001. — V.43. — P.301−306.
- Gall FP, Tonak J, Altendorf A. Multivisceral resections in colorectal cancer. Dis Colon Rectum. 1987.-V.304.-P. 337−41.
- Galliani I. Histochemical and ultrastructural study of the human pineal gland in the course of aging. / Galliani I., Frank F. et al. // J. Submicrosc. Cytol. Pathol. -1989. -V.21. P.571−578.
- Girouard H. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. / Girouard H., et al. // J. Hypertens. 2001. — V. 19. — P. 1369−1377.
- Gold P. Spesific carcinoembryonic antigens of the human digestive system. / Gold P. Freedman S.O. // J. Exp. Med. 1965. — V.122. — P. 467−481.
- Gordon F.H. A randomised placebo-controled trial of a humanized monoclonal antibody to a4 integrin in* active Crohn’s disease. / Gordon F.H., Lai C W. Y>., Hamilton M.I., Allison M.C. et al. // Gastroenterology. 2001. — V. 121. — p- 268−274.
- Green J. Nicotine and ulcerative colitis. / Green J., Richardson C, Rhodes J. // Inflammatory bowel disease monitor. 2001. — V. 2 — № 3. — P. 73−77.
- Green J. Nicotine enemas in active ulcerative colitis a pilot study. / Green J., Thomas G.A.Oi, Rhodes J. et al. // Aliment. Pharmacol. Ther. — 1997. — V. 11 P. 859−863.
- Greenstein A.J. Cancer in universal and leftside ulcerative colitis: factors determining risk. / Greenstein A.J., Sachar D.B., Smith H. et al. // Gastroenterology.- 1979. -77.-290.
- Gross V. Tumor necrosis factor and-its receptors. / Gross V., Andus T., Rogler G., Kojouharoff G. // Inflammatory bowel disease From Bench to Bedside // International Symposium on IBD. — 1996. — P. 175−183.
- Gyde S. Screening of colorectal cancer in ulcerative colitis: dubious benefits and-high costs. / Gyde S. // Gut. 1990. — V. 31. — P. 1089.
- Hamilton T. Influence of environmental light and melatonin upon mammary tumour induction. / Hamilton T. // Brit. J. Surg. 1969. — V.56. — P. 764−766.
- Hanauer S.B. Medical management of ulcerative colitis. / Hanauer S.B. // IBD, salicylates and other relevant therapies. Proceeding of the International IBD Symposium. — London. — 1999. — P. 41−46.
- Hansen J. Increased breast cancer risk among women who work predominantly at night. / Hansen J. // Ann. Epidemiol. 2001. — V.12. — P.74−77.
- Harlow H.J. Effect of melatonin on the force of spontaneous contractions of in vitro rat small and large intestine. / Harlow H.J., WeeklyB.L. // J. Pineal Res. -1986.-V.3.-P.277−284.
- Hasegawa H. K-ras gene mutations in early colorectal cancer. / Hasegawa H., Ueda M., Watanabe M. // Oncogene, 1995. V. 10. — № 7. — P. 1413−1416.
- Hayash N. No-touch isolation technique reduces intra-operative shedding of tumor cells the portal vein during resection of colorectal cancer. / Hayash N,
- EgamiH- Kai M, Kurusu Y, Takano S, Ogawa M. // Surgery. 1999. — V.125. -P. 369−74.
- Heuschen U.A. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. / Heuschen U.A., Hinz U., Allemeyer E.H., Stem J. // Gastroenterology. 2001.-V. 120.-P. 841−847.
- Hill M.J. Metabolic epidemiology of dietary factors in large bowel cancer. / Hill M.J. // Cane. Res.. 1975. — V.35. — P. 3398−3402.
- Hill S.M. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. / Hill S.M., Blask D.E. // Cancer Res. 1988. — V.48. — P.6121−6126.
- Hiwatashi N. HLA antigens in inflammatory bowel disease. / Hiwatashi N., Kikuchi T., Masamune O. et al. // Totohu J. Exp. Med. 1980. — V. 131. — P. 381−385.
- Hodgson H.J.F. Extraintestinal manifestations of inflammatory bowel disease. / Hodgson H.J.F. // Inflammatory bowel disease / Edit. By G. Jamerot. 1992. -P. 515−536.
- HogezandR.A. van, New therapies for inflammatory bowel disease: an update on chimeric anti-TNFa antibodies and IL-10 therapy. / HogezandR.A. van, Verspaget H. W. // Scand. J. Gastroenterol. 1997. — V. 32 (suppl. 223). — P. 105−107.
- Hordjik M.L. Risk of cancer in inflammatory Bowel Disease: why are the results in the rewiewed literature so varied? / Hordjik M.L., Chivananda S. // Scand. J. Gastroenterol. 1989. — V. 24. — P. 70−74.
- Home J.A. Seasonal changes in the circadian variation of oral temperature during wakefulness. / Home J.A., Coyne S. // Experientia. 1975. — V.31. -P.464−470.
- Huether G. The metabolic fate of infused L-tryptophan in men: possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites. / Huether G., Hajak G., et al. // Psychopharmacology. -1992. V. 106. — P.422−432.
- Huether G. Effects of indirectly acting 5-HT receptor agonists on circulating1 melatonin in rats. / Huether G. Poeggeler B., Blanke J. et al. // Eur J. Pharmacol. 1993. — V.238. — P.249−254.
- Hunter J.A. En bloc resection of colon-cancer adherent to other organs. / Hunter J.A., Ryan J.A., Schultz P. //Am J Surg. 1987. — V.154. — P. 67−71.
- Hyde G.M. Review article: the management of severe ulcerative colitis. / Hyde G.M., Jewell D.P. // Aliment. Pharmacol. Ther. 1997. — V. 11. — P. 419−424.
- Hampe J. Genetics and inflammatory bowel disease. / Hampe J., Schreiber S. // IBD, salicylates and other relevant therapies. International IBD Symposium. -London. — 1999.-P. 21−30.v
- Igarashi M. Ammonia as an Accelerator of Tumor Necrosis Factor Alpha-Induced Apoptosis of Gastric Epithelial Cells in Helicobacter pylori Infection. Infect / Igarashi M.5 Kitada Y., Yoshiyama H. et al.// Immun. 2001. — Vol.69. -P. 816−821.
- Infantolino D. An immunohis-tochemical study crypt cell proliferation in ulcerative colitis. / Infantolino D., Biasin M.R., D’Inca R., Sartor M.S. et al. JJ Inflammatory bowel diseases. Falk Symposium № 76. 1994. — P. 22.
- Jagelman D.G. Single-dose cefotetan versus multiple- dose cefoxitin as prophylaxis in colorectal surgery. / Jagelman D.G., Fabian T.C., Nichols R.L., Stone H.H., Wilson S.E., Zellner S.R. // Am J Surg. 1988. — V.155. — P. 71−6,
- Jain S.K. Inflammatory bowel disease and colon cancer: a review. / Jain S.K., Peppersorn M.A. // Dig. Dis. Sci. 1997. — V. 15. — P. 243−252.
- Jamal A. Cancer statistics. / Jamal A. et al. //CA Cancer J Clin. 2002. — V.52. -P. 23−47.
- Jansson B. Geographic mappings of colorectal cancer rates- a retrospect of studies: 1974−1978. Cancer Detect. Prev. 1985. — V.8. — P.341.
- Jarnerot G. Working team report: Medical treatment of refractory distal ulcerative colitis. / Jarnerot G., Lennard-Jones J., Brynskov J. // Gastroenterol. Int. 1991. -V. 4.-P. 93−98.
- Jemal A. Cancer Statistics. / Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. // CA Cancer J Clin. 2003. — V.53. — P.5−26.
- Jewell D.P. Management of severe ulcerative colitis. / Jewell D.P. // IBD, salicylates and other relevant therapies. Proceeding of the International IBD Symposium. — London. — 1999. — P. 55−62.
- Jones R.N. Single-dose surgical prophylaxis using ticarcillin/clavulanic acid (Timentin): a prospective, randomized comparison with cefotaxime. / Jones R.N., Wojeski W.V. // Diagn Microbiol Infect Dis. 1987. — V.7. — P.219−23.
- Jones N.L. Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of H. pylori infection / Jones N.L. // Amer. J. Pathol. -1997.-Vol.151.-P.1695−1803.
- Kaistura J. Apoptotic and necrotic myocyte cell death / Kaistura J., Cheng W-, Reiss K. et al. // Lab.Invest. 1996. — Vol.74. — P.86−107.
- Kamm M.A. Inflammatory bowel disease. / KammM.A. //-Martin Dunitz Ltd-UK. 1999.
- Kanasava S. VEGF, basic-FGF, and TGF-beta in Crohn’s disease and. ulcerative colitis: a novel mechanism of chronic intestinal' inflammation^ / Kanasava S., Tsunoda T., Onuma E. et al. //Am J Gastroenterol. 2001 Mar- 96(3): 822−8.
- Kanemitsu T. Study of the cell proliferation kinetics in ulcerative colitis, adenomatous polyps, and cancer. / Kanemitsu T., Koike A., Yamamoto S. «// Cancer. 1985. -V. 56. -№ 5.-P. 1094−1098.
- Kaneto H. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells / Kaneto H., Fujii J., Seo H.G. et al. // Diabetes. 1995. — Vol.44, N7. — P.733−738.
- Karasek M. Melatonin inhibits the proliferation of estrogen-induced rat pituitary tumor cells in vitro. / Karasek M., Kunert-Radek 3., Steipen H., Pawkikowski M. // Neuroendocrinol. Lett. 1988. — V.10. — P. 135−140.
- Karlen P. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis: a population-based case control study. / Karlen P., KornfeldD. et al. // Gut. 1998.-V.42.-P. 711−716.
- Katz J.A. Probiotic therapy in IBD. / Katz J.A., Fiocchi C. // Inflammatory bowel disease monitor. 2001. — V. 2 — № 4. — P. 106−111.
- Kavaliers M. Caicium channel involvement in magnetic fields Inhibition of morphine induced analgesia. / Kavaliers M., Ossenkopp K.P. // Naunyn Schmiedebergs Arch. Pharmacol. 1987. — V.336. -P.308−315.
- Keller K. The use of proliferating cell nuclear antigen (PCNA) expression and intraepithelial lymphocyte count in the differential diagnosis of inflammatorybowePdisease. / Keller K, Koch M.K. // Italian J. Gastroenterol.- 1994. V. 26. -5.-P. 233−237.
- Kennaway D.J. A specific radioimmunoassay for melatonin in biological tissue and fluids and its validation by gas chromatography-mass spectrometry. / Kennaway D.J., Frith R.G., et al. // Endocrinology. 1977. — V. l 10. — P.2186−2194.
- Kern S.E. Molecular genetic profiles of colitis-associated neoplasms. / Kern S.E., Redston M., Seymour A.B. et al. // Gastroenterology. 1994. — V. 107. -P.420−428.
- Kikuchi Y. Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones. / Kikuchi Y., Kita T., Miyauchi M. et al. // Gynecol. Oncol. 1989. — V.32. — P. 60−64.
- Kim P. S. Optimum duration of treatment with 6-merkaptopurine for Crohn’s disease. / Kim P. S., Zlatanic J., Korelitz B.I., Glein G. W. // Am. J. Gastroenterol. 1999.-V.94.-P. 3254−3257.
- Klump B. Distribution of cell populations with DNA aneuploidy and p53 protein expression in ulcerative colitis. / Klump B., Holzmann K., Kuhn A. et al. // Eur. J. Gastroenterol. Hepatol. 1997. — V. 9. — № 8. — P. 789−794.
- Korf H.W.The pineal organ, its hormone melatonin, and the photoneuroendocrine system. / Korf H.W. Schomerus C., Stehle J.H. // Adv. Anat. Embryol. Cell Biol. 1998. — V. 146. — P. l-100.
- Korhonen H. Seasonal changes in platform use by farmed blue foxes (Alopex-Lagopus). / Korhonen H., Niemela P., Tuuri H. // Appl. Animal Behav. 1996. -V.48.-P.99−114.
- Kotake K. Changes in Colorectal Cancer During a 20. / Kotake K. et al.// -year Perio Japan Dis C&R. 2003. — V.46.- P.32-^3.
- Kothari L. Effect of continuous light on the incidence of 9,10-dimethyl-l, 2-benzanthracene induced mammary tumors in female Holtzamn rats. / Kothari L., Shah P.N., Mhatre M.C. // Cancer Lett. 1982. — V.16. — P:313−317.
- Kroesen A.J. 5-ASA maintenance therapy in IBD. / Kroesen A.J. // International meeting „Prevention of colorectal cancer with'5—ASA“. — Copenhagen. May. -2000.
- Kulmann F. Expession of proliferating cell nuclear antigen (PCNA) and Ki67 in dysplasia in inflammatory bowel disease. / Kulmann F., Fadaie M., Gross V., Knuchel R. et al. // Gastroenterol., Hepatol. 1996. — V. 8. — 4. — P. 371−379.
- Kvetnoy I. M- The diffuse neuroendocrine system and extrapineal melatonin: / Kvetnoy I.M., Sandvik A.K., Waldum H.L. // J. Mol. Endocrinol. 1997a. -V.18. — P. l-3.
- Kvetnoy I.M. Extrapineal melatonin nontraditional localization and possible significance for oncology. / Kvetnoy I.M., Yuzhakov V.V. // In: Advances in Pineal Research. London. — 1994. — V.7. — P. 199−212.
- Kvetnoy I.M. Extrapineal melatonin: advances in microscopical identification of hormones in endocrine and non- endocrine cells. / Kvetnoy I.M., Yuzhakov V.V. // Microscopy & Analysis. 1993. — V.21. — P.27−29.
- Kvetnoy I.M. APUD cells: modern strategy of morpho-fimctional analysis. / Kvetnoy I.M., Yuzhakov V.V., Raikhlin N.T. // Microscopy & Analysis.. -1997b.-V.48.-P. 25−27.
- Laffer U. Randomized trial of adjuvant perioperative chemotherapy in radically resected colorectal cancer (SAKK40/80). / Laffer U, Maubach R, Metzger U, et al. // Proc Am Soc Clin Oncol. 1998. — V.17. — P.256a.
- Langholz E. Epidemiology of IBD and colorectal cancer in IBD. / Langholz E. // International meeting „Prevention of colorectal cancer with 5-ASA“. -Copenhagen. May. — 2000.
- Langholz E. Colorectal cancer risk and mortality in patients with ulcerative-colitis. / Langholz E., Munkholm P., Davidsen M., Binder V. // Gastroenterology. 1992.-V. 103.-P. 1444−1451.
- Lapin V. Pineal influence on tumor. / Lapin V. // Progr. Brain Res. 1979. -V.52. — P.523−533.
- Lapin V. Effect of some molecular weight sheep pineal fractions and melatonin on different tumors in rats and mice. / Lapin V., Ebels I. // Oncology. 1976. -V.33.-P. 110−113.
- Larsson L.-I. On the possible existence of multiple endocrine, paracrine and neurocrine messengers in secretory system. / Larsson L.-I. // Invest. Cell Pathol. 1980.-V.3.- P.73−85.
- Lashner BiA. Effect of folate-supplementation on-the icidence of displasia. and cancer in chronic ulcerative colitis. A case-control study. / Lashner B.A., Heidenreich P.A., Su G.L. et al. // Gastroenterology. 1989- - 97. — 255.
- Lee P.P. Melatonin and its reseptors in the gastrointestinal tract. / Lee P.P., Pang S.F. //Biol. Signals. 1993.- V.2. — P. 181−193.
- Lemann M. Methotrexate in Crohn’s disease: long-term efficacy and toxity. / Lemann M., Zenjari T., Cosnes J., Mesnard B. //- Am. J. Gastroenterol. 2000. -V. 95.-P. 1730−1734.
- Lemus-Wilson A. Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. / Lemus-Wilson A., Kelly P.A., Blask D.E. //Brit. J. Cancer. 1995.- V.72. — P.1435−1440.
- Lennard-Jones J.E. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. / Lennard-Jones J.E., Melville D.M., Morson B.C. et al II Gut. 1990. — V. 31. — P. 800−806.
- Lewis J.D. Azatioprine for maintenance of remission in in Crohn’s disease: benefits outweigh the risk of lymphoma. / Lewis J.D., Sanford-Schwartz J., Lichtenstein G.R. // Gastroenterology. 2000. — V. 118. — P. 1018−1024.
- Lewy A.J. Melatonin shifts human circadian rhythms according to a phase -response curve. / Lewy A.J., Ahmed S., Jackson M.L. Sack R.L. // Chronobiol. Int. 1992. V.9. -P.380−392.
- L’Hermite-Baleriaux M. Is melatonin really an in vitro inhibtor of human breast cancer cell proliferation. / L’Hermite-Baleriaux M., de Launoit Y. // In vitro Cell Dev. Biol. 1992. — V. 28A. — P. 583−584.
- Lindberg B. Twenty years' colonoscopic surveillance of patients with ulcerative colitis. / Lindberg B., Persson B., Veress B. et al. // Scand. J. Gastroenterol. -1996.-V. 31-P. 1195−1204.
- Lissoni P. Is there a role for melatonin in supportive care? / Lissoni P. // Support Care Cancer. 2002.- V.10. -P.110−116.
- Lofberg R. Latest views on cancer in inflammatory bowel diseases. / Lofberg R. // Research and clinical forums. 1995. — V. 17. — № 1. — P. 19−31.
- Lofberg R. Medical treatment of distal active ulcerative colitis. / Lofberg R. // IBD, salicylates and other relevant therapies. Proceeding of the International IBD Symposium. — London — 1999. — P. 47−54.
- Loftus E. V. Crohn’s disease in Olmsted County, Minnesota 1940−1993: incidence, prevalence, survival. / Loftus E. V. // Gastroenterology. 1998. — V. 114 (6).-P. 1160−1168.
- Long X., Wu G., Gaa S.T., Rogers T.B. Inhibition of protein phosphatase-1 is linked to phosphoiylation of p53 and apoptosis. // Apoptosis. 2002. —№ 1. — P. 31−39.
- Lopez-Kostner F. Management and causes of acute large bowel obstruction,.,/ Lopez-Kostner F, Hool GR, Lavery IC. // Surg Clin North Am. 1997. — V.77. -P. 1265−90.
- Maestroni G. The melatonin-immune system-opiod network. / Maestroni G., Conti A. // In: Advances in pineal research. London. — 1990. — V.4. — P.233−241.
- Maestroni G.J. Immuno-derived opioids as mediators of the immuno-enhancing and anti-stress action of melatonin. / Maestroni G.J., Conti A. // Acta. Neural. (Napoli). 1991. — V. 13. — P.356−360.
- Maestroni G.J.M. The immunotherapeutic potential of melatonin. / Maestroni G.J.M. // Expert. Opin. Invest. Drugs. 2001. — V. 10. — P.467−476.
- Malchow H. European Cooperative Crohn’s disease study (ECCDS): results of drug treatment. / Malchow H., Ewe K., Brand J. W. et al. // Gastroenterology. -1984. -V. 86. P. 249−266.
- Mango G. Apoptosis, oncosias, necrosis / Mango G., Joris I. // Amer. J. Pathol. 1995.-Vol.146.-P.3−15.
- Marion J.F. The medical management of acute and chronic UC. / Marion J.F. // Acta Gastro-Enterologica Belgica. 2000. — V. 63. — Fase. 3. — P. 284−288.
- Marsoni S. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. / Marsoni S. // Semin Oncol. 2001. — V.28- - P:14−9.
- Marzioni M. Autocrine/paracrine regulation of the growth of the biliary tree by the-neuroendocrine hormone serotonin. / Marzioni M., Glaser S, Francis K, Marucci L et al. \ Gastroenterology. 2005 Jan-128(l): 121−37.
- Martins A.C. Clinical features and immunoexpression of p53, MIB-1, and proliferative cell nuclear antigen in adrenal neoplasms. / Martins A.C., Colonna A J., Tussi J.R. et al'. //J. Urol.2005 Jun- 179(6):2138−42.
- Matsuda K. Ulcerative colitis with overex-pression of p53 preceding overt histological abnormalities of the epithelium. / Matsuda K., Watanabe H., Ajioka Y. et al. // J. Gastroenterol. 1996. — V. 31. -№ 6. — P. 860−867.
- Me Alindon M.E. Cytokines and the gut. / Me Alindon M: E., Mahida.Y.R. // Eur. J. Gastroenterol. Hepatol. 1997. — V. 9. — № 11. — P: 1045−50.
- Mediavilla M"D. Effect of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene. / Mediavilla M.D., Guezmez A., Ramos S. et al. // J. Pineal Res. 1997. — V. 22. — P. 86−94.
- Meltzer S.J. Molecular biology of colitis associated neo-plasia. / Meltzer S.J., Greenwald B. D: // Malignancy and chronic inflammation in the gastrointestinal tract -new concepts. Kluwer Academic Publishers. — 1995. — P. 141−152.
- Mendelof A.I. The epidemiolody of chronic inflammatory bowel disease. / MendelofA.I. // Inflammatory Bowel Disease / Ed. by G. Jarnerot. 1992. — P. 15−34.
- Minagawa. Extension of tht frontiers of surg. Indication in the treatment of liver metastatic colorectal cancer Ann Surg. / Minagawa et al //- 2000. V.231. — P. 487−99.
- Moelling R. Genetic events in* colon' carcinoma. / Moelling R., Radzwill, Rommel C. et al. // Malignancy and chronic inflammation in, the gastrointestinal tract new concepts. Kluwer Academic Publishers. — 1995- - P. 93−97.
- Moertel C.G. An evalution of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. / Moertel C.G., Fleming T.R., MacDonald J.S., et al. // JAMA. 1993. — V.270. — P. 943−947.
- Molis T.M. Melatonin modulation of estrogen-regulated"proteins, growth factors, and proto-oncogens in human breast cancer. / Molis T.M., Springs L.L., Jupiter Y., Hill S.M. // J. Pineal Res. 1995. — V.18. — P. 93−103.
- Mortensen N.J. Ileo-anal pouches clinical outcomes. / Mortensen N.J. // IBD, salicylates and other relevant therapies. — Proceeding of the International IBD Symposium. — London- - 1999. — P. 63−68.
- Mozart M. Nitric oxide induces apoptosis in Nalm-6, a leukaemia cell line with low cyclin Eprotein levels / Mozart M., Scuderi R., Celsing F. et al.// Cell Prolif. 2001 Dec- 34(6):369−78.
- Munkholm P. Cancer chemoprevantion in IBD pharmacoeconomics? / Munkholm P. // International meeting „Prevention of colorectal cancer with 5-ASA“. -Copenhagen. — May. — 2000.
- Munkholm P. Frequency of glucocorti-coid resistence and dependency in Crohn’s disease. / Munkholm P., Langholi E., Davidsen M., Binder V. // Gut. -1994. V. 35. -P. 360−362.
- Murch S.H. //High endothelin -1 immunoreactivity ins Grohn’s disease and ulcerative colitis / Murch S. H, Braegger C.P., Sessa W.C., et al. //Lancet. 1992 Feb 15- 339(8790):381−5.
- Navazo L. Oral microemulsion cyclossporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. / Navazo L, Salata H., Morales S., Dorta M.C. et al. // Scand. J. Gastroenterol. 2001. — V. 36. — P. 610−614.
- Neri B. Melatonin as biological response modifier in cancer patients. / Neri B., De Leonardis V., Gemelli M.T. et al. // Anticancer Res. 1998. — V.18. — P.1329−1332.
- Nordinger. Surg. Resection of colorectal carcinoma metastases to liver. / Nordinger et al //- 1996. V.771. — P. 1254 — 62.
- Northover J. Carcinoembryonic antigen and recurrent colorectal cancer. / Northover J. // Gut. 1986. — V.27. — P. 1117−122.
- Ozaki Y. Prensece of melatonin in plasma and urina of pinealectomised rats. / Ozaki Y., Lynch H. // Endocrinology. 1976. — V.99. — P.641−644.
- Padol I. Therapeutic effects of the endothelin receptor antagonist Ro 48−5695 in the TNBS/DNBS rat model of the colitis / Padol I., Huang J.Q., Hogaboam C.M. et al. //Eur J Gastroenterol Hepatol. 2000 Mar- 12(3):257−65.
- Pallone F. Regulatory cytokines in inflammatory bowel disease. / Pallone F., Monteleone G. I I Aliment. Pharmacol. Then. 1996. — V. 10. — Suppi. 2. — P. 75−79.
- Panes J. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. / Panes J., Esteve M., Carbe E., Hinojosa J. et al. // Gastroenterology. 2000. — V. 119. — P. 903−908.
- Panzer A. The validity of melatonin as an oncostatic agent. / Panzer A., Viljoen M. // J. Pineal Res. 1997. — V.22. — P. 184−202.
- Papadakis K.A. Role of cytokines in the pathogenesis of inflammatory bowel disease. / Papadakis K.A., Targan S.R. // Ann. Rev. Med. 2000. -V. 51. — P. 289−298.
- Pardridge W.M. Transport of albumin-bound melatonin through blood-brain barrier. / Pardridge W.M., Mietus L.J. // J. Neurochem. 1980. — V.34. P.1761−1763.
- Paus R. Neirobiologie der Haut: Apoptose / Paus R., Menrad A., Czameizki B. // Hautarzt. 1995.- Bd. 46, N3. — S. 285−303.
- Pearse A.G.E. The cytochemistry and ultrastructure of polypeptide hormone-producing cell of the APUD series and the embryologic and pathologic implications of the concept. / Pearse A.G.E. // J. Histochem. Cytochem. 1969. — V.17.-P.303−313.
- Pierrefiche G. Antioxidant activity of melatonin in mice. / Pierrefiche G., Topall G., Courboin G. ET AL. // Res. Commun. Chem. Pathol. Pharmacol. 1993. -V.80.-P.211 -223.
- Pickett C.A. Altered expression of cyclins and cell ingibitors in papillary thyroid cancer: prognostic implications. / Pickett C.A., Agoff S.N., Widman T.J. et al. // Thyroid. 2005 May- 15(5):461−73.
- Piliponsky A.M. Regulation of apoptosis in mast cells / Piliponsky A.M., Levi» Schaffer F.//Apoptosis. 2000. — Nov. — 5(5):435−41.
- Pinczowski D. Risk faktors for colorectal cancer in patients with ulcerative colitis: a case-control study. / Pinczowski D., Ekbom A., Baron J. et al. // Gastroenterology. 1994.-V. 107.-P. 117−120.
- Polak J.M. Immunocytochernistry of the diffuse neuroendocrine system. / Polak J.M., Bloom S.R. // In: Immunocytochernistry: modern methods and applications. Bristol. — 1986. — P.328−348.
- Polk H.C. Postoperative wound infection: a prospective study of determinant factors andprevention. / Polk H.C., Lopez-Mayor J.F. // Surgery. 1969. -V.66. -P.97−103.
- Poon A.M. Melatonin and 2125J. iodomelatonin binding sites in the human colon. / Poon A.M., Mak A.S., Luk H.A.T. // Endocr. Res. 1996. — V.22. -P.77−94.
- Porschen R. DNA aneuploidy in Crohn’s disease and ulcerative colitis: rezults of a comparative flow cytometric study. / Porschen R., Robin U., Schumacher A. et al. //
- Pozharisski K.M. Experimental intestinal cancer research with special reference to human pathology. / Pozharisski K.M., Likhachev A J., Klimashevski V.F., Shaposhnikov J.D. // Adv. Cancer Res. 1979. — V.30. — P. 165−237.
- Prantera C. Metronidasol plus ciprofloxacine for the treatment of active Crohn’s disease: a randomised controlled trial. / Prantera C, ZannoniF., Scribano M.L. et al // Am. J. Gastroenterol. 1996. — V. 91. — P. 328−332.
- Present D.H. Infliximab for the treatment of fistulas in patiens with Crohn’s disease./ Present D.H., Rutgeerts P., Targan S., Hanauer S.B. et al. // N. Engl. J. Med. — 1999.-V. 340.-1398−1405.
- Pukkala E. Incidence of cancer among Finnish arline cabin attendants, 1967−92. / Pukkala E., Auvinen H., et al. // Br. Med. J. 1995. — V.311. — P.649−652.
- Rachmilewitz D. Prostaglandins, leukotrienes, platelet activating factor and nitric oxide. / Rachmilewitz D. // Inflammatory bowel disease From Bench to Bedside // International Symposium on IBD. — 1996. — P. 133−138.
- Radford-Smith G.L. The balance between pro- and anti-inflammatory cytokines in the intestine. / Radford-Smith G.L. // Inflammatory bowel disease. -International Symposium on IBD. 1995. — P. 298−304.
- Rafnsson V. Risk of breast cancer in female flight attendants: a population-based study (Iceland). / Rafnsson V., Tulinius H., et al. // Cancer Causes Control. 2001. — V. 12. — P.95−101.
- Raikhlin N.T. The APUD system (Diffuse endocrine system) in normal and pathological states. / Raikhlin N.T., Kvetnoy I.M. // Physiol. Gen. Biol. Rev. -1994. -V.8. P. 1−44.
- Raikhlin N.T. The APUD system (diffuse endocrine system) in normal and pathological states. / Raikhlin N.T., Kvetnoy I.M. // Physiol. Gen. Biol. Rev. -1994. V.8. — P.1−44.
- Raikhlin N.T. Melatonin and enterochromoffme cell. / Raikhlin N.T., Kvetnoy I.M. //ActaHistochem. 1976. — V.55. -P.19−25.
- Raikhlin N.T. Melatonin may be synthesised in enterochromoffme cell. / Raikhlin N.T., Kvetnoy I.M., Tolkachev V.N. // Nature. 1975. — V. 155. -P.344−345.
- Reed J.C. Bcl-2 and regulation of programmed cell death / Reed J.C. // J. Cell.Biol. 1994. — Vol.124. — P. l-6.
- Reddy D.P. Overview of diet and colon cancer. / Reddy D.P. // Prog.Clin.Biol. Res. .- 1988.- V.279. P. 111.
- Reinacher-Schick A. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. / Reinacher-Schick A., Seidensticker F., Petrasch S., Reiser M. et al. // Endoscopy. 2000. -V. 32. -P. 245−254.
- Reiter R. J". Pineal melatonin: cell biology of its synthesis and of its physiological interactions. / Reiter R. J. // Endocrin. Rev. 1991. — V.12.— P.151−180.
- Reiter R.J. Melatonin: that ubiquitously acting pineal hormone. / Reiter R.J. // New Physiol. Sei. 1991. — V.6. -P.223−228.
- Reiter R.J. The pineal and its hormones in the control of reproduction in mammals. / Reiter R.J. // Endocr. Rev. 1980. — V. 1. — P. 109−131.
- Reiter R.J. Antioxidant capacity of melatonin: a novel action not requiring a receptor. / Reiter R.J., Poeggeler B., Tan D.X. et al. // Neuroendocrinol.Lett. — 1993. V.15. — P. 103−116.
- Reiter R.J. Melatonin, free radicals and cancer initiation. In: Advances in pineal research. / Reiter R.J., Poeggeler B., Tan D.X. et al. // London.. 1994. — V.7. -P. 211−228.
- Reumaux D. Distinct production of autoantibodies to nuclear components in ulcerative colitis and Crohn’s disease. / Reumaux D., Meziere C., ColombelJ. F, Duthilleul P. et al. // Clin. Immunol. Immunopathol. 1995. — V. 77. — P. 349^ 357.
- Ricart E. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. / Ricart E., Panaccione R., Loftus E., Tremain W. // Am. J. Gastroenterol. 2001. — V. 96. — P. 722−729.
- Ricart E. Successful management of Crohn’s disease of the ileoanal pouch with infliximab. / Ricart E., Panaccione R., Loftus E., Tremain W. // Gastroenterology. 1999.-V.I 17.-P. 429A32.
- Rice J. Effect of light therapy on salivary melatonin in seasonal affective disorder. / Rice J., Mayor J., et al. // Psychiatry Res. 1995. — V.56. — P.221−228.
- Riddell R.H. Dysplasia in inflammatory bowel disease. / Riddell R.H., Goldman E., Ransohoff D.E. et al. // Hum. Path. 1983. — V. 66. — P. 669−678.
- Rioux J.D. Absence of linkage between inflammatory bowel disease and selected loci on chromosomes 3, 7, 12 and 16. / Rioux J.D., Daly M.J., Green T., Stone V. et al. // Gastroenterology. 1998. — V. 115. — № 5. — P. 1062−1065.
- Rutgeerts P. A critical assessment of new therapies in inflammatory bowel diseases. / Rutgeerts P. // J. Gastroenterol. Hepatol, 2002. V. 17. — Suppl. -SI77 QR.
- Rutgeerts P. Management of perianal Crohn’s disease. / Rutgeerts P. // Scand.l. Gastroenterol., 2000. V. 14 (suppl. C). — 7C.
- Rutgeerts P. Predictability of postoperative course of Crohn’s disease. / Rutgeerts P., GeboesK., Vantrappen G., BeylsJ. et al. // Gastroenterology.""1990.-V. 99.-P. 956−963.
- Sachar D.B. Maintenance management of Crohn’s disease. / Sachar D.B. // IBD, salicylates and other relevant therapies International IBD Symposium. -London.- 1999.-P. 77−82.
- Sack R.L. melatonin administration to blind people: phase advances and entrainment. / Sack R.L., Lewy A.J., Blood M. L., et al. // J. Biol. Rhythms.1991. V. 6. — P.249−261.
- Sagar S.M., Singh G., Hodson I., et al. Nitric oxide and anticancer therapy || Cancer Treat. Rev. 1995. -V.21. — P. 159−181.
- Sanborn WJ. Steroid-dependent Crohn’s disease. / Sanborn WJ. //Scand: J. Gastroenterol. 2000.-V. 14(suppl.C).-17C.
- Sanborn W.J. An engineered human antibody to TNF (GDP571) for active Crohn’s disease: a randomized double-blind placebo control trial. / Sanborn W.J., Feagan B.J., Hanauer S.B., Present D.H. et al. // Gastroenterology. 2001 -V. 120.-P. 1330−1338.
- Sanborn W.J. Transdermal nicotine for mildy to moderate active ulcerative colitis: a randomized, double-blined placebo controlled trial. / Sanborn W.J., Tremaine W., Offord R.P. // Ann. Int. Med. 1997. — V. 126. — P. 364−371.
- Sands B.E. Medical therapy of steroid-resistant Crohn’s disease. / Sands B.E. // Scand. J. Gastroenterol., 2000. V. 14 (suppl. C). — 33C. w"
- Sands B.E. Preliminary evaluation of safety and activity of recombinant human interleukine 11 in patients with active Crohn’s disease. / Sands B.E., Bank S., Sninsky C.A., Robinson M. // Gastroenterology, 1999 V. 117. — P. 58−64.
- Sands B.E. Infliximab in the treatment of severe of steroid-refractory ulcerative colitis: a pilot study. / Sands B.E., Tremaine W.J., Sanborn W.J., Rutgeerts P. et al. //IBD, 2001—V. 7—P. 83−88.
- Sartor R.B. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. / Sartor R.B. // Gastroenterology & Hepatology. 2006. — V.3 (№ 7).-P. 102.
- Sartor R.B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. / Sartor R.B. // Am. J. Gastroenterol. 1997. -V. 92. — Suppl. 12. — S5-S11.
- Satake N. The inhibitory action of MEL on the contractile response to 5-hydroxytryptamine in various isolated vascular smooth muscles. / Satake N., Shibata S., et al. // Gen. Pharmacol. 1986. — V.17. — P.553−558.
- Satsangy J. The genetics of inflammatory bowel diseases (Leading article). / Satsangy J., Jewell D.P., Bell J.I. // Gut. 1997. — V. 40. — P. 572−574.
- Sasaki M.3 Jordan P., Jon., et al. Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kappaB //BMC Gastroenterol. 2002 Apr 24- 2(1):9.
- Scheele et al 1995 Resection of colorectal liver metastases Word J Surg. -1995. V.19. — P.59−71.
- Schernhammer E.S. Rotating night shifts and risk of breast cancer in women participating in the nurses health study. / Schernhammer E.S., Laden F., et al. // J. .Natl. Cancer Inst-2001.-V.93.-P. 1563−1568.
- Schpach W. Histological changes in the colonic mucosa following irrigation with short-chain fatty acid. / Schpach W., Mi/Her Y.G., Boxberger K, Dusel G. et al. // Gastroenterol., Hepatol. 1997. — V. 9. — P. 163−168.
- Schreiber S. Aspects of the immunology of inflammatory bowel diseases. / Schreiber S. // Recent Advances in the Pathophysiology of Gastrointestinal and Liver Diseases. Nantes. — July 1997.-P. 133−171.
- Schreiber S. Use of anti-tumor necrosis factor agents in inflammatory bowel diseases. European guidelines for 2001−2003. / Schreiber S., Campieri M., Colombel J.F., van Deventer S.J.H. et al. // Int. J. Colorectal Dis. 2001. — V. 16. -№ 1 -P. 1−11.
- Schreiber S. Safety and efficacy of recombinant human interleukin~10 in chronic active Crohn’s disease. / Schreiber S., Fedorak R.N., Nielsen O.H., Wild G. // Gastroenterology. 2000. -V. 119. — P. 1461−1472.
- Schreiber S. Genetics of Crohn disease, an archetypal inflammatory barrier disease. / Schreiber S., Rosenstiel P., Albrecht M., Hampe J., Krawczak M. // Nature reviews|gtnttics. 2005. — V.6. — P. 376−388.
- Schreiber S. Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. / Schreiber S., Heining Т., ThieleH.-G., Raedler A. // Gastroenterology. 1995. — V. 108. — № 5. — P. 1434−1444.
- Schrieber S. Tumor necrosis factor-a and interleukin 1(3 in relapse of Crohn’s disease. / Schrieber S., Nicolaus S., Натре J., Hdmling J. et al. // Lancet. 1999. -V. 353.-p. 459−461.
- Sengupta S. Diatary- fiber and colorectal neoplasia. / Sengupta S., Tjandra J .J., Gibson P.R. //Dis. Colon Rectum. 2001. -V. 44. — P. 1016−1033.
- Shellard S.A. Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro. / Shellard S.A., Whelan R.D.H., Hill B.T. // Brit. J. Cancer. 1989. — V. 60. — P. 288−290.
- Shibata.S. Vasorelaxing action of melatonin in rabbit basilar artery. / Shibata.^., et al. // Gen. Pharmacol. 1989. — V.20. — P.677−680.
- Simmang CL. Practice parameters for detection of colorectal neoplasms. / Simmang CL, Senatore P, Lowry A, et al. // Dis Colon Rectum. 1999. — V.42. -P. 1123−9.
- Solas A. Heparin attenuates TNF-a induced inflammatory response though CDllb dependent mechanism. / Solas A., Sans M., Soriano A. // Gut. 2000. -V. 47. — P. 88−96.
- Solary E. The rolo of apoptosis in the pathogenesis and treatment of diseases / Solary E., Dubrez L., Eymin B. // European Respiratory. 1996. — Vol. 9, N 6. -P.1293−1305.
- Solcia E. Endocrin cell producing regulatory peptides. / Solcia E., Usellini L., et al. // In: Regulatoiy Peptides. Basel. — 1989. — P.220−246.
- Steele G Zamcheck N. The use of carcinoembryonic antigen in the clinical management of patients with colorectal cancer. / Steele G Zamcheck N. // Cane. Det. Prev. 1985. — V.8. — P.421.
- Steinbach G. The effect of celecoxib, a cyclooxigenase-2 inhibitor, in familial adenomatous polyposis. / Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H. et al. // N. Engl. J. Med. 2000. — V. 342. — P. 1946−1952.
- Steinhart H. Maintenance Therapy in Crohn’s disease. / Steinhart H. // Scand. 1. Gastroenterol. 2000. — V. 14 (suppl. C). — 23C.
- Steinhart H. Steroid resistant and steroid dependent Crohn’s disease. / Steinhart H. // IBD, salicylates and other relevant therapies. Proceeding of the International IBD Symposium. — London. — 1999. — P. 83−90.
- Stevens R.G. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer). / Stevens R.G., Rea M.S. // Cancer Causes Control. 2001. — V. 12. — P.279−287.
- Strack J.M. Phenotypic plasticity, cellular-dynamics, and epithelial turnover of the intestine of Japanese-quail (Coturnix Coturnix-Japonica). / Strack J.M. // J. Zool. — 1996. — V.238. — P.53−79.
- Sugita A. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age of onset on colitis-cancer interval. / Sugita A., Sachar D.B., Bodian C. et al.//Gut. 1991.-32.-P. 167.
- Sundler F. The neuroendocrine system of the gut. / Sundler F. et al. // Acta Oncol.- 1989.-V.283.- P.303−314.
- Surgical Resection of Colorectal Liver Metastases in Patient with Expanded Indications. Dis C&R. 2007. — V.4. — P. 478−87.
- Sze S.F. Antiproliferative effect of pineal indoles on cultured tumor cell lines. / Sze S.F., Ng T.B., Liu W.K. // J. Pineal Res. 1993. — V. 14. — P. 27−33.
- Targan S.R. Biology of inflammation in Crohn’s disease: mechanism of action. of anti TNF-a therapy. / Targan S.R. // Scand. J. Gastroenterol. — 2000. — V. 14 (suppl. C.-13C.
- Tenforde T.S. Interaction of extremely low freguency electric and magnetic fields with humans. / Tenforde T.S., Kaune W.T. // Health Physics. 1987. — V.53. — P.585−606.
- Tomita-R. Physiologic studies on Nitric oxide in rat small bowel isografts / Tomita R., Fujisaki S., Park E., et al. // World J. Surg. 2003 May 13
- Torkvist L. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. / Torkvist L., Thorlacius H., Sjoqvist U., Bohman L. et al. // Aliment. Pharmacol.Ther. 1999.-V. 13.-P. 1323−1328.
- Trock B. Dietary fiber, vegetables and colon cancer: critical review and metaanalyses of the epidemiological evidence. / Trock B., Lanza E., Greenwald P. // J Nat. Cane. Inst. 1990. — V.82. — P. 650.
- Tromm A. Oral mesalazine for the treatment of Crohn’s disease: clinical efficacy with respect to pharmacokinetic properties. / Tromm A., Griga N., May B. // Hepatogastroenterology. 1999.-V.46.-P. 3124−3135.
- Tuitou Y. Human aging and melatonin. Clinical relevance. / Tuitou Y. // Exn. Gerontol. 2001. — V.36. — P. 1083−1100.
- Tuitou Y. Modifications of circadian and circannual rhythms with age. / Tuitou Y., Bogdan A., Haus E., Tuitou C. // Exp. Gerontol. 1997. — V.32. — P.603−614.
- Turunen U.M. Long-term treatment of ulcerative colitis with cyprofloxacin: A prospective double-blined, placebo-controlled study. / Turunen U.M., Farkkila M.A., Hakala K., Seppdld K. et al. // Gastroenterology. 1998. — V. 115. — № -P. 1072−1078.
- Tynes T. Incidence of breast cancer in Norwegian female radio and telegraph operators. / Tynes T., Hannevik M., et al. // Cancer Causes Control. 1996. -V.7.- P. 197−204.
- Van Assche G. The use of humonised anti-interleukin-2 receptor antibodies (Zenapax) in refractory ulcerative colitis. / Van Assche G., Dalle I., Neman M. // Gastroenterology. 2001.-V. 120 (suppl. 1).- 1445.
- Van Deventer S.J.H: Targeting TNF-a as a key in the inflammatory process in Crohn’s disease the mechanism of action of infliximab. / Van Deventer S.J.H. // Aliment. Pharmacol. Ther. — 1999. — V. 13. — Suppl. — P. 43−48.
- Van Deventer S.J.H. Tumor necrosis factor and Crohn’s disease. / Van Deventer S.J.H. //Gut. 1997.-40 (4). — P. 443−148.
- Vanya D Peltekova. Functional variants of OCTN cation trasporter genes are associated with Crohn’s disease. / Vanya D Peltekova, Richard F Wintle- Laurence A Rubin, et al.// Nature Genetics. 2004. — V.4. — P. 43−50."
- Vatn M.H. Ulcerative colitis the first attack: diagnosis and outcome. / Vatn M.H., Mourn B., Jahnsen J., Bermclev T. // IBD, salicylates and other relevant therapies-Proceeding of the International IBD Symposium-London. — 1999 -P. 31−40.
- Verhofstad A.A.J. Immunocytochemical localization of noradrenaline and serotonin. / Verhofstad A.A.J, et al. // In: Immunocytochemistry. Practical applications in biology and pathology. Bristol. — 1983. — P. 143−168.
- Vetuschi A. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats / Vetuschi A., Latella G., Sferra R., et al.//Dig Dis Sci. 2002Jul- 47(7): 1447−57.
- Vialli M. Histology of the enterochromoffine cell. / Vialli M. // In: 5-Hydroxytryptamine and related indolealkylamines: handbook of experimental pharmacology.- Berlin. 1966. — V.19. — P. 1−65.
- Vollrath L. The pineal' organ. / Vollrath L. // In: «Handbuch der mikrospopischeni anatomie des menschen». Oksche A. Vollrath L. (eds.). V. IV, Part 10. Berlin & New York: Springer-Verlag. 1981- P. 1−665.-
- Vries J.E. Interleukin-10: immunosuppressive and anti-inflammatory activities // Inflammatory bowel disease. / Vries J.E. // International Symposium. 1995 -P. 68−76.
- Wajs E. Melatonin and N-acetylserotonin two pineal indoleamines inhibiting the proliferation of the jejunal epithelial cells in the rat. / Wajs E., Lewinski A. // Med. Sei. Res. — 1988. — V.16. — P. l 125−1126.
- Wehr T.A. A «clock for all seasons» in the human brain. / Wehr T.A. // Prog. Brain. Res. 1996. — V. l 11. — P.321−342.
- Weissbluth L. Infant colic: the effect of serotonin and melatonin circadian rhythms on the intestinal smooth muscle. / Weissbluth L., Weissbluth^ M. // Med. Hypotheses. 1992. — V.39. — P. 164−167.
- Wingrin G. Mortality and cancer morbidity in a cohort Swedish brewery workers. / Wingrin G., Englander V. // Int. arch. Occup. Env. Health. 1990. -V.62.-P. 253.
- Wolmark N. NSABP trials in colon cancer. / Wolmark N, Colangelo L, Wieand S. // Semin Oncol. 2001. — V.28(9). — P. 9−13.
- Yaga K. Tryptophan loading increases daytime serum melatonin in intact and pinealectomized rats. / Yaga K., Reiter R.J. // Life Sei. 1993. — V.52. -P.1231−1238.
- Yamamoto. The Risk of Multiple Primary Malign. With colorectal Carcinoma D./ Yamamoto, et al. I I C&R. 2006. — V.49. — P. 30−36.
- Yu H.-S. «Melatonin. Biosynthesis, physiological effects, and clinical applications». / Yu H.-S., Reiter R.J., eds. //Boca Raton, FL: CRC Press. 1993. -P.527.
- Yang F.G. Peroxisome proliferator-activated receptor gamma ligands iduce cell cycle arrest and apoptosis in human renal carcinoma cell lines./ Yang F.G., Zhang Z.W., Xin D.Q. et al. // Acta Pharmacol Sin. 2005 Jun- 26(6):26(6):753−61.
- Zerek-Melen G. The opposite effect of high and low doses of melatonin on mitotic activity of the mouse intestinal epithelium. / Zerek-Melen G., Lewinski A., Kulak J. // Endokrynil. Pol. 1987. — V.38. — P.317−323.
- Zimmerman M.J. Cytokines and mechanisms of action of glu-cocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn’s disease. / Zimmerman M.J., JewellD.P. //Aliment. Pharmacol. Ther. 1996 -V. 10. -Suppl. 2. -P. 93−98.
- Zisapel N. Inhibition by melatonin of protein secretion and growth of melanoma cells in culture. / Zisapel N., Bubis M. // Adv. Pineal Res. 1994. — V. 7. — P. 259−268.